ArticleBiomolecules2025
Enhancing CD8
Yongshuai Jiang, Yingying Wei, Ziyang Li, Zhenghang Huang, Junsheng Dong, Weijuan Gong, Li Qian
Abstract read
In one paragraphArticle in Biomolecules, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
7 authors.
Yongshuai JiangSchool of Basic Medical Sciences & School of Public Health, Faculty of Medicine, Yangzhou University, Yangzhou 225009, China.ORCID 0000-0003-1380-7826 Yingying WeiSchool of Basic Medical Sciences & School of Public Health, Faculty of Medicine, Yangzhou University, Yangzhou 225009, China.
Ziyang LiSchool of Basic Medical Sciences & School of Public Health, Faculty of Medicine, Yangzhou University, Yangzhou 225009, China.
Zhenghang HuangSchool of Basic Medical Sciences & School of Public Health, Faculty of Medicine, Yangzhou University, Yangzhou 225009, China.
Junsheng DongJiangsu Key Laboratory of Zoonosis, Yangzhou University, Yangzhou 225009, China.
Weijuan GongSchool of Basic Medical Sciences & School of Public Health, Faculty of Medicine, Yangzhou University, Yangzhou 225009, China.
Li QianSchool of Basic Medical Sciences & School of Public Health, Faculty of Medicine, Yangzhou University, Yangzhou 225009, China.
Funding
China Postdoctoral Science Foundation 2022M722689Jiangsu Provincial Double-Innovation Doctor Program (2022) noJiangsu Provincial Graduate Research and Practice Innovation Program KYCX25_4096LvYang Golden Phoenix Plan, Yangzhou City (2022) noNational Natural Science Foundation of China 82402045
6 · The paper itselfAbstract
PRMT5, a type II methyltransferase catalyzing symmetric dimethylation of arginine residues, has emerged as a promising therapeutic target in various cancers. However, the precise mechanism by which PRMT5 mediated the tumor immune microenvironment, particularly CD8
Indexed as
CD8-Positive T-LymphocytesChemokine CXCL10Protein-Arginine N-MethyltransferasesUterine Cervical NeoplasmsAnimalsCell Line, TumorDisease ProgressionFemaleGene Expression Regulation, NeoplasticHumansLymphocytes, Tumor-InfiltratingMiceMice, KnockoutSignal TransductionTumor MicroenvironmentChemokine CXCL10CXCL10 protein, humanPRMT5 protein, humanPrmt5 protein, mouseProtein-Arginine N-MethyltransferasesCD8+ T cellscervical cancerCXCL10PRMT5tumor microenvironment
Identifiers
PMID41463372
PMCPMC12731132
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390